Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

LRR Energy L.P. Posts Q1 Profit Of $3.8 Mln - Quick Facts

RELATED NEWS
Trade LRE now with 

LRR Energy L.P. (LRE: Quote) reported that net income for the first-quarter 2012 was $3.8 million, or $0.17 per limited partner unit. Total revenues for the latest-quarter were $24.0 million.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.32 per share on revenues of $24.75 million for the quarter. Analysts' estimates typically exclude special items.

LRR Energy continues to expect its 2012 capital expenditures to total approximately $21.2 million, of which approximately $18.0 million is maintenance capital.

Notwithstanding the Red Lake field shut-in and the Pecos Slope field curtailment, LRR Energy said it is still comfortable with its 2012 production guidance range of 5,700 - 6,100 Boe/d. The company said its production rate for April 2012 was approximately 5,875 Boe/d.

Click here to receive FREE breaking news email alerts for LRR Energy, L.P. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved sharply lower over the course of the trading day on Wednesday, adding to the modest weakness seen in the two previous sessions. With the losses on the day, the major averages fell to their lowest closing levels in over a month. Democrats have climbed into the lead on a generic ballot, according to the results of a new CNN/ORC International poll, although the results may not be as positive for the party as they first appear. With spending on private and public construction both showing notable decreases, the Commerce Department released a report on Wednesday showing an unexpected drop in U.S. construction spending in the month of August.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.